MDT Medtronic plc Loading...

From BSX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
Apr 22 ◎
Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific Cor… BSX Q1 FY26 call
The US EP business (including PFA) is expected to be roughly flat to low single-digit growth for 2Q-4Q, a significant deceleration from historical performance, as BSX loses more share than anticipated to Medtronic, J&J, and Abbott. — This indicates that the US PFA competitive dynamic is shifting faster than expected, and BSX's leadership position is being challenged more intensely in the near term.
MDT
MED
13:00
Feb 04 ◎
Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific Cor… BSX Q4 FY25 call
US EP market penetrated ~70% with PFA in 2025; BSX expects market growth to normalize to ~15% in 2026, down from an estimated 18-20% in Q4 2025, with BSX explicitly planning to lose share due to competitive launches. — Signals the high-growth phase in US PFA is maturing; competitive share gains are expected to accelerate, pressuring all players on volume and pricing.
MDT
MED

About MDT Analyst Coverage

Buzzberg tracks MDT (Medtronic plc) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Latest voices: Mike Mahoney.